ES2613754T5 - Use of glycopyrrolate for treating tachycardia - Google Patents

Use of glycopyrrolate for treating tachycardia

Info

Publication number
ES2613754T5
ES2613754T5 ES12709151T ES12709151T ES2613754T5 ES 2613754 T5 ES2613754 T5 ES 2613754T5 ES 12709151 T ES12709151 T ES 12709151T ES 12709151 T ES12709151 T ES 12709151T ES 2613754 T5 ES2613754 T5 ES 2613754T5
Authority
ES
Spain
Prior art keywords
glycopyrrolate
treating tachycardia
tachycardia
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12709151T
Other languages
English (en)
Spanish (es)
Other versions
ES2613754T3 (es
Inventor
Susan Snape
Robert Tansley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Nxera Pharma UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2613754(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103770.2A external-priority patent/GB201103770D0/en
Priority claimed from GBGB1202256.2A external-priority patent/GB201202256D0/en
Application filed by Nxera Pharma UK Ltd filed Critical Nxera Pharma UK Ltd
Publication of ES2613754T3 publication Critical patent/ES2613754T3/es
Application granted granted Critical
Publication of ES2613754T5 publication Critical patent/ES2613754T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
ES12709151T 2011-03-04 2012-03-05 Use of glycopyrrolate for treating tachycardia Active ES2613754T5 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1103770.2A GB201103770D0 (en) 2011-03-04 2011-03-04 Novel use
GB201103770 2011-03-04
GBGB1202256.2A GB201202256D0 (en) 2012-02-09 2012-02-09 Novel use
GB201202256 2012-02-09
PCT/GB2012/050478 WO2012120284A1 (en) 2011-03-04 2012-03-05 Use of glycopyrrolate for treating tachycardia

Publications (2)

Publication Number Publication Date
ES2613754T3 ES2613754T3 (es) 2017-05-25
ES2613754T5 true ES2613754T5 (en) 2026-01-22

Family

ID=45841526

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12709151T Active ES2613754T5 (en) 2011-03-04 2012-03-05 Use of glycopyrrolate for treating tachycardia

Country Status (20)

Country Link
US (2) US20140080890A1 (enExample)
EP (1) EP2680841B2 (enExample)
JP (1) JP6129081B2 (enExample)
KR (1) KR101853997B1 (enExample)
CN (1) CN103501781B (enExample)
AR (1) AR085616A1 (enExample)
AU (1) AU2012226608B2 (enExample)
BR (1) BR112013022523A2 (enExample)
CA (1) CA2828640C (enExample)
CL (1) CL2013002542A1 (enExample)
EA (1) EA025287B1 (enExample)
ES (1) ES2613754T5 (enExample)
GE (1) GEP201706640B (enExample)
IL (1) IL227972A (enExample)
JO (1) JO3510B1 (enExample)
MD (1) MD4369C1 (enExample)
MX (1) MX356025B (enExample)
TW (1) TWI536988B (enExample)
WO (1) WO2012120284A1 (enExample)
ZA (1) ZA201306130B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1011220B1 (pt) 2009-05-29 2020-03-10 Pearl Therapeutics, Inc. Composição farmacêutica administrável a partir de um inalador de dose medida compreendendo um meio de suspensão compreendendo um propelente, duas ou mais espécies diferentes de partículas de agente ativo e uma ou mais espécies de partículas respiráveis em suspensão
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
AU2013100009B4 (en) * 2013-01-04 2013-03-14 Novartis Ag Treatment of chronic obstructive pulmonary disease
TR201902687T4 (tr) * 2013-03-15 2019-03-21 Pearl Therapeutics Inc İri parçacıklı kristal malzemelerin koşullandırılması için yöntemler ve sistemler.
MA50680A (fr) * 2014-09-09 2020-08-05 Vectura Ltd Formulation comprenant glycopyrrolate, procédé et appareil
BR112017009315A2 (pt) * 2014-11-05 2017-12-19 Glenmark Pharmaceuticals Ltd composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios.
PT3346990T (pt) 2015-09-09 2020-05-18 Vectura Ltd Método de moagem a jato
HUE054071T2 (hu) * 2016-05-25 2021-08-30 Claudia Mattern Kétrészes mûanyag öntvénykészlet
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
WO2018167180A1 (en) * 2017-03-15 2018-09-20 Vectura Limited Method and formulation
KR102669919B1 (ko) * 2019-07-10 2024-05-28 한미약품 주식회사 흡입용 캡슐제 및 이의 제조방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
BE718438A (enExample) * 1967-08-23 1968-12-31
NL8104929A (nl) * 1980-11-12 1982-06-01 Alza Corp Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan.
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
EP0909163A4 (en) * 1996-07-01 1999-06-09 Sepracor Inc METHOD AND MEANS FOR TREATING URINE INCONTINENCE USING THE (S, R) -GLYCOPYRROLATE ENANTIOMER MAINLY
GB9808470D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
KR20000013487A (ko) * 1998-08-10 2000-03-06 정주영 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물
PT1131059E (pt) 1998-11-13 2003-07-31 Jago Res Ag Po seco para inalacao
GB9826284D0 (en) * 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE10136404A1 (de) * 2001-07-26 2003-02-20 Johannes Wohlrab Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ATE399027T1 (de) * 2004-02-06 2008-07-15 Meda Pharma Gmbh & Co Kg Neue kombination von anticholinergen und beta mimetika zur behanldung von atemwegserkrankungen
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
US7923455B2 (en) 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
GB0703999D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
EP2440196A4 (en) 2009-06-09 2013-01-02 Elevation Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ADMINISTRATION OF BETA 2 NEBULIZED AGONIST OR A COMBINATION OF BETA 2 NEBULIZED AGONIST AND ANTICHOLINERGIC

Also Published As

Publication number Publication date
EP2680841B2 (en) 2025-10-22
JO3510B1 (ar) 2020-07-05
GEP201706640B (en) 2017-03-27
EP2680841A1 (en) 2014-01-08
KR20140020950A (ko) 2014-02-19
WO2012120284A1 (en) 2012-09-13
TW201247198A (en) 2012-12-01
EA201391275A1 (ru) 2014-02-28
CA2828640A1 (en) 2012-09-13
JP2014514271A (ja) 2014-06-19
MD4369C1 (ro) 2016-04-30
ZA201306130B (en) 2014-04-30
US10695321B2 (en) 2020-06-30
EP2680841B1 (en) 2016-12-28
KR101853997B1 (ko) 2018-05-02
MD4369B1 (ro) 2015-09-30
IL227972A0 (en) 2013-09-30
US20160143880A1 (en) 2016-05-26
US20140080890A1 (en) 2014-03-20
TWI536988B (zh) 2016-06-11
AR085616A1 (es) 2013-10-16
CN103501781B (zh) 2016-10-26
JP6129081B2 (ja) 2017-05-17
CN103501781A (zh) 2014-01-08
MX2013009838A (es) 2016-09-27
ES2613754T3 (es) 2017-05-25
BR112013022523A2 (pt) 2016-11-29
CA2828640C (en) 2017-01-03
EA025287B1 (ru) 2016-12-30
NZ614603A (en) 2016-01-29
AU2012226608B2 (en) 2015-11-26
AU2012226608A1 (en) 2013-09-12
IL227972A (en) 2017-06-29
CL2013002542A1 (es) 2014-07-11
MD20130069A2 (ro) 2014-03-31
MX356025B (es) 2018-05-09

Similar Documents

Publication Publication Date Title
ES2613754T5 (en) Use of glycopyrrolate for treating tachycardia
IL262611A (en) Treatment for lipodystrophy
EP2757887A4 (en) PYRROLOPYRIDINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF HIV
EP2776126A4 (en) DEFINITION OF EFFECTIVE DEFIBRILLATION
EP2717855A4 (en) PROCESSING METHODS
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
ZA201407411B (en) Process for treating biomass
IL225623A0 (en) Psoriasis treatment methods
IL253421B (en) Compounds for the treatment of fibrosis (Leifat)
EP2852403A4 (en) METHOD FOR MODIFYING TISSUE
SG11201501026TA (en) Composition for treating psoriasis
HUE047320T2 (hu) Terméketlenség kezelésére szolgáló kompozíció
HUE038149T2 (hu) Eljárás acél kezelésére
GB201121950D0 (en) Treatment process
LT2460509T (lt) Kompozicija, skirta karpų gydymui
ZA201409502B (en) Composition for treatment of warts
GB201110659D0 (en) composition for skin treatment
GB201110653D0 (en) Composition for skin treatment
GB201105056D0 (en) Treatment process
IL208779A0 (en) Process for surface treatment
IL213610A0 (en) Composition for treating dermatological conditions
GB201110602D0 (en) Methods of treatment
GB201109737D0 (en) Methods of treatment
GB201113479D0 (en) Finishing treatment
GB201121044D0 (en) Treatment of solutions